Eric Wallace
Nephrology · Birmingham, ALNPI 1871706960
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 63.4% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $42,751, 3.2 times the $13,483 reported in 2019. Among nephrology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $1373.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$109K
- Chiesi USA, Inc.$45K
- Kyowa Kirin, Inc.$9K
- Amicus Therapeutics, Inc.$7K
- Withings, Inc.$587
- Baxter Healthcare$172
- plus $726 from 7 others
Across 198 payments — averaging $5495.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$477K
- Sanofi$447K
- Sanofi US Services Inc.$164K
- Covidien LP$300
What the payments were for
- Consulting fees$95,44056%
- Speaking & faculty fees$44,66426%
- Travel & lodging$27,62616%
- Food & beverage$3,9672%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 71 | $108,923 |
| Chiesi USA, Inc. | 22 | $45,363 |
| Kyowa Kirin, Inc. | 8 | $8,815 |
| Amicus Therapeutics, Inc. | 7 | $7,108 |
| Withings, Inc. | 1 | $587 |
| Baxter Healthcare | 4 | $172 |
| Sanofi US Services Inc. | 1 | $139 |
| Intuitive Surgical | 2 | $135 |
| Novartis | 1 | $127 |
| Novo Nordisk | 1 | $125 |
| Fresenius USA Marketing, Inc. | 5 | $86 |
| Vantive US Healthcare LLC | 1 | $64 |
| Amgen | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FABRAZYME$44,582
- ELFABRIO$19,619
- CRYSVITA$8,665
- NO PRODUCT DISCUSSED$704
- GALAFOLD$139
- Da Vinci Surgical System$129
- Fabhalta$127
How this compares
$171,696 in reported general payments places this provider in the 95th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ElfabrioPegunigalsidase Alfa-Iwxj | 14 | $493,095 |
| AuryxiaFerric Citrate | 15 | $10,632 |
| Clonidine | 31 | $4,330 |
| Sevelamer Carbonate | 26 | $4,100 |
| Gentamicin Sulfate | 44 | $1,576 |
| ConstuloseLactulose | 19 | $860 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $444 |
| Carvedilol | 25 | $364 |
| Potassium Chloride | 23 | $363 |
| Lactulose | 24 | $306 |
| Amlodipine Besylate | 29 | $219 |
| Losartan Potassium | 19 | $170 |
| Gabapentin | 19 | $154 |
| Furosemide | 22 | $131 |
| Fluconazole | 12 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Chiesi USA, Inc.Elfabrio | $45,363 | $493,09514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 164 nephrology providers in Alabama.
Other nephrology in Birmingham
- Dana RizkBirmingham$196K
- David WarnockBirmingham$128K
- Michal MrugBirmingham$73K
- Vineeta KumarBirmingham$59K
- Ashita TolwaniBirmingham$56K
- Song Ching OngBirmingham$36K
- Orlando GutierrezBirmingham$26K
- Ammar AlmehmiBirmingham$26K
- Jared CookBirmingham$25K
- Timmy LeeBirmingham$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.